Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Novo Integrated Sciences Inc (NVOS)

Novo Integrated Sciences Inc (NVOS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,015
  • Shares Outstanding, K 19,055
  • Annual Sales, $ 12,570 K
  • Annual Income, $ -13,210 K
  • 60-Month Beta -1.78
  • Price/Sales 0.80
  • Price/Cash Flow N/A
  • Price/Book 0.42
Trade NVOS with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.54
  • Most Recent Earnings $-0.16 on 04/15/24
  • Latest Earnings Date 05/24/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4160 +26.35%
on 04/19/24
0.6500 -19.14%
on 04/17/24
+0.0367 (+7.51%)
since 03/25/24
3-Month
0.4160 +26.35%
on 04/19/24
0.8349 -37.05%
on 02/20/24
-0.1818 (-25.70%)
since 01/25/24
52-Week
0.4160 +26.35%
on 04/19/24
5.3840 -90.24%
on 09/13/23
-0.5534 (-51.29%)
since 04/25/23

Most Recent Stories

More News
Novo Integrated Sciences Signs Agreements for an Unsecured, Non-dilutive Debt Instrument with a Principal Sum of $70,000,000

Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today announced the issuance of an unsecured 15-year $70,000,000 promissory note with RC Consulting LLC in favor of SCP...

NVOS : 0.5256 (+0.11%)
Novo Integrated Sciences Reports Fiscal Full Year 2022 Financial Results

Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple...

NVOS : 0.5256 (+0.11%)
Novo Integrated Sciences Provides Update on Certain Current Actions and Events

Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today provides an update with respect to certain actions and events, as follows:

NVOS : 0.5256 (+0.11%)
Novo Integrated Sciences Announces Receipt of Notice from Nasdaq

Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today reported that it received a notice on January 25, 2023 from the Listing Qualifications Department of The Nasdaq Stock...

NVOS : 0.5256 (+0.11%)
Novo Integrated Sciences Provides Update on Certain Current Actions and Events

Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today provides an update with respect to certain actions and events, as follows:

NVOS : 0.5256 (+0.11%)
Novo Integrated Sciences Announces Receipt of Notice from Nasdaq

Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today reported that it received a notice (the “Notice) on December 15, 2022 from the Listing Qualifications Department...

NVOS : 0.5256 (+0.11%)
Novo Integrated Sciences’ Subsidiary, Clinical Consultants International, Signs Consulting Agreement with Pharmaceutical Research & Development Company, Sarfez Pharmaceuticals, Inc.

Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), and Clinical Consultants International LLC (“CCI”), a Novo wholly-owned subsidiary, today announced the signing of a...

NVOS : 0.5256 (+0.11%)
Novo Integrated Sciences’ Subsidiary, Clinical Consultants International, Signs Sales & Consulting Agreement with Smart Healthcare Solution Provider, TiaTech USA Inc.

Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), and Clinical Consultants International (“CCI”), a Novo wholly-owned subsidiary, today announced the signing of a Sales...

NVOS : 0.5256 (+0.11%)
Novo Integrated Sciences’ Subsidiary, Clinical Consultants International, Signs Sales & Consulting Agreement with Tranquility Lifestyle Solutions

Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), and Clinical Consultants International (‘CCI’), a Novo wholly-owned subsidiary, today announced the signing of a Sales...

NVOS : 0.5256 (+0.11%)
Pre-Market Brief: Stocks Mixed After Indices Stage Sharp Reversal

December S&P 500 futures (ESZ22) are trending down -0.20% this morning after three major US benchmark indices made a dramatic recovery, closing sharply higher after an earlier sell-off on Thursday as the...

ESZ22 : 3,871.47s (-0.66%)
IMRA : 6.32 (+15.96%)
EAR : 2.57 (-4.10%)
NVOS : 0.5256 (+0.11%)
RETA : 172.36 (+0.02%)
RLMD : 3.70 (-4.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Novo Integrated Sciences Inc. is a provider of multi-dimensional primary healthcare services and products principally in Canada and the U.S. It deliver or intend to deliver, multidisciplinary primary health care related services and products through the integration of medical technology, advanced therapeutics...

See More

Key Turning Points

3rd Resistance Point 0.5967
2nd Resistance Point 0.5733
1st Resistance Point 0.5495
Last Price 0.5256
1st Support Level 0.5023
2nd Support Level 0.4789
3rd Support Level 0.4551

See More

52-Week High 5.3840
Fibonacci 61.8% 3.4862
Fibonacci 50% 2.9000
Fibonacci 38.2% 2.3138
Last Price 0.5256
52-Week Low 0.4160

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar